CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of thyroid cancer.
  
  LEARNING OBJECTIVES

  • Appraise the efficacy and safety of multitargeted tyrosine kinase inhibitors for radioactive iodine (RAI)-refractory advanced thyroid cancer, and discern how these agents can be optimally employed in patient care.
  • Evaluate patient- and disease-related factors to appropriately select and sequence available therapeutic options for RAI-refractory thyroid cancer.
  • Recognize the spectrum and prevalence of potentially targetable genomic alterations in patients with thyroid cancer, and discuss the means by which these alterations contribute to tumor growth and proliferation.
  • Recall FDA-approved and guideline-endorsed diagnostic platforms for biomarker testing for patients with advanced thyroid cancer, and refine clinical testing algorithms by assessing the advantages and disadvantages of available assays.
  • Analyze available safety and efficacy results with novel RET inhibitors for patients with RET-driven thyroid cancer, and appropriately integrate these agents into treatment algorithms.
  • Recall other validated biomarkers of response to targeted treatment (eg, NTRK fusions) for advanced thyroid cancer, and counsel patients harboring these abnormalities about personalized therapeutic recommendations.
  • Use the results of genomic analyses to integrate available and emerging novel targeted therapies into treatment decision-making for patients with thyroid cancer.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Lori J Wirth, MD
  The Elizabeth and Michael Ruane Chair of Endocrine Oncology
  Associate Professor
  Harvard Medical School
  Medical Director, Head and Neck Oncology
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Advisory Committee: Blueprint Medicines, Eisai Inc, Exelixis Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Lilly; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics, PDS Biotechnology.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Blueprint Medicines, Exelixis Inc, Genentech, a member of the Roche Group, and Lilly.
  
  Release date: August 2021
  Expiration date: August 2022